Opportunity to Acquire a Premier Turnkey CRO Facility
A unique chance has arisen to acquire a world-class, fully operational Contract Research Organization (CRO) facility through an upcoming bankruptcy sale. This premier facility, once occupied by AmplifyBio, is designed specifically for advanced research applications and comes fully equipped with a suite of laboratory tools and intellectual property. The sale is officially sanctioned by the U.S. Bankruptcy Court, ensuring a transparent bidding process.
Facility Specifications and Features
This expansive property, covering approximately 205,000 square feet, includes 65,000 square feet dedicated to specialized laboratory space and a state-of-the-art 64-room vivarium. The vivarium is designed to facilitate a one-way traffic flow, enhancing operational efficiency and reducing contamination risks. Additionally, the facility boasts a fully equipped on-site surgical suite, positioning it as an ideal location for high-complexity research activities.
Designed for Advanced Research
The architectural and operational design of this facility supports a variety of crucial scientific endeavors, specifically in the development of pharmaceuticals and biotechnology innovations. The integrated laboratories provide comprehensive services such as toxicology assessments and bioanalytical evaluations, both essential for advancing contemporary therapeutic solutions.
A Brief Look at AmplifyBio's Legacy
Founded in 2021, AmplifyBio leveraged over $200 million in investments to emerge rapidly as a key player in the advanced therapy domain. The company focused on revolutionary areas, including gene editing and T cell therapies, with facilities strategically located in multiple states. They were known for offering a full range of pre-clinical research and good manufacturing practice (GMP) services, catering to diverse biopharmaceutical clients.
A Strategic Investment for Potential Bidders
Jurisdictional authorities emphasize the strategic advantages for buyers interested in this facility. Joel Schneider, a senior vice president at Hilco Real Estate, remarked on the unique opportunity this sale presents. The comprehensive setup of Class-A laboratory and office spaces makes this facility adaptable for various advanced research purposes.
Highlighting Advanced Equipment
Brent Bonham, a senior managing director at Hilco Commercial Industrial, accentuated the collection of sophisticated equipment available with the facility. This includes essential tools and instruments required for immediate research applications, which could save significant time and costs for any interested CRO or research organization.
Extensive Intellectual Property Portfolio
One of the standout features of this sale is the patent portfolio previously held by AmplifyBio. David Peress, an executive vice president at Hilco Streambank, noted the significance of this portfolio, which encompasses a wide array of clinically validated innovations across immunotherapy and cell engineering. With a total of 119 active patents, this intellectual property could provide considerable advantages in personalized medicine.
Bidding Process and Next Steps
Prospective bidders must submit their proposals no later than the designated deadline, accompanied by a completed Asset Purchase Agreement. This document provides detailed guidance regarding the sale process. Interested parties are encouraged to access further information about bid procedures, which have been officially approved by the court, to ensure compliance.
Contact for Inquiries
Those desiring to explore this exceptional opportunity further should reach out to Chet Evans for on-site visits or inquiries. The facility's details can be obtained through Hilco Real Estate's official communication channels.
Frequently Asked Questions
What is the nature of the facility being sold?
The facility is a technologically advanced CRO environment previously used by AmplifyBio, encompassing laboratory space, a vivarium, and a surgical suite.
Who manages the sale process?
The sale is managed by Hilco Global under the supervision of the U.S. Bankruptcy Court, ensuring a transparent bidding environment.
When is the bid deadline?
Bids must be received by the specified deadline, typically detailed in the official bidding documents.
What assets are included in the sale?
The sale includes the real estate, equipment, and intellectual property associated with the AmplifyBio portfolio.
How can interested bidders get more information?
Bidders can contact Hilco Global representatives for detailed bid procedures and access to facility inspections.
